share_log

Tharimmune | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Tharimmune | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Tharimmune | S-8：員工福利計劃證券登記
美股sec公告 ·  06/13 04:20
牛牛AI助理已提取核心訊息
On June 12, 2024, Tharimmune, Inc., a biopharmaceutical company, filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission (SEC). This filing is to register an additional 159,733 shares of common stock under the company's Amended and Restated 2023 Omnibus Equity Incentive Plan. The plan, which was amended to include an 'evergreen' provision, will automatically increase the number of shares available each year starting January 1, 2025, until January 1, 2033. The increase will be the lesser of 5% of the outstanding common stock or a number determined by the Board. The registration statement incorporates by reference the company's previous filings, including its Annual Report on Form 10-K for the year ended December 31, 2023, and Quarterly Reports on Form 10-Q for the quarter ended March 31, 2024. Tharimmune's CEO, Randy Milby, and other executives have signed the filing, which also includes the company's indemnification provisions for directors and officers, as permitted by Delaware law.
On June 12, 2024, Tharimmune, Inc., a biopharmaceutical company, filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission (SEC). This filing is to register an additional 159,733 shares of common stock under the company's Amended and Restated 2023 Omnibus Equity Incentive Plan. The plan, which was amended to include an 'evergreen' provision, will automatically increase the number of shares available each year starting January 1, 2025, until January 1, 2033. The increase will be the lesser of 5% of the outstanding common stock or a number determined by the Board. The registration statement incorporates by reference the company's previous filings, including its Annual Report on Form 10-K for the year ended December 31, 2023, and Quarterly Reports on Form 10-Q for the quarter ended March 31, 2024. Tharimmune's CEO, Randy Milby, and other executives have signed the filing, which also includes the company's indemnification provisions for directors and officers, as permitted by Delaware law.
2024年6月12日，生物製藥公司Tharimmune公司向美國證券交易所（SEC）提交了S-8表格註冊聲明。該申報是爲了在該公司修訂後的2023年股權激勵計劃下注冊159,733股普通股。該計劃經修訂，包括了一項“常青”條款，將在2025年1月1日至2033年1月1日期間每年自動增加可用股份數量，增加數量爲未流通普通股的5%或董事會確定的數量中較小的那一個。該註冊聲明包括參考公司的以往申報，包括其於2023年12月31日結束的年度10-K申報和截至2024年3月31日的季度10-Q申報。Tharimmune公司的CEO Randy Milby和其他高管已簽署該文件，幷包括了公司的董事和高管的賠償規定，依德拉瓦州法律規定。
2024年6月12日，生物製藥公司Tharimmune公司向美國證券交易所（SEC）提交了S-8表格註冊聲明。該申報是爲了在該公司修訂後的2023年股權激勵計劃下注冊159,733股普通股。該計劃經修訂，包括了一項“常青”條款，將在2025年1月1日至2033年1月1日期間每年自動增加可用股份數量，增加數量爲未流通普通股的5%或董事會確定的數量中較小的那一個。該註冊聲明包括參考公司的以往申報，包括其於2023年12月31日結束的年度10-K申報和截至2024年3月31日的季度10-Q申報。Tharimmune公司的CEO Randy Milby和其他高管已簽署該文件，幷包括了公司的董事和高管的賠償規定，依德拉瓦州法律規定。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。